|Bid||0.8500 x 1100|
|Ask||0.8900 x 800|
|Day's Range||0.8515 - 0.8958|
|52 Week Range||0.3820 - 3.5780|
|Beta (3Y Monthly)||4.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 —.
CHESTERBROOK, Pa., July 31, 2019 -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.
NEW ORLEANS , July 19, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced the appointment of Barry Shin as Chief Financial Officer. Mr. Shin joins Trevena with extensive experience advising biopharmaceutical companies through merger and acquisition (M&A) and financing transactions. He was previously Managing Director in the Healthcare Investment Banking Group at Mizuho Securities. Prior to joining Mizuho Securities, he was a Managing Director in Guggenheim Securities’ Healthcare Investment Banking Group from 2012 to 2017. From 2005 to 2012, he served in positions of increasing responsibility within the Healthcare Investment Banking Group of Piper Jaffray. From 2001 to 2005, he advised healthcare and technology companies in financing and M&A transactions as a corporate attorney. Mr. Shin received a B.Sc.
The publication: “APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the µ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty”, with lead author, Neil Singla, M.D., CEO of Lotus Clinical Research, is available online at https://doi.org/10.1111/papr.12801.
CHESTERBROOK, Pa., June 20, 2019 -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Trevena, Inc. (TRVN). On November 7, 2017, the Company reported that it had submitted a New Drug Application (“NDA”) for Oliceridine, its lead product candidate. On November 2, 2018, the Company disclosed that it received a response from the Food and Drug Administration (“FDA”) denying the NDA for Oliceridine due to inadequate data to support approval.
CHESTERBROOK, Pa., May 29, 2019 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.
— Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to.
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.
Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to.
The publication, “APOLLO-1: A randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein–biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy,” with lead author, Eugene R Viscusi, M.D.,Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, is available online at https://www.dovepress.com/journal-of-pain-research-archive41. “In this study, oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain,” said Dr. Viscusi.
As we've seen over the last few years, tech companies have invested resources in artificial intelligence, automation, quantum computing, and augmented reality to pioneer technologies to drive society into the future. ParcelPal Technology Inc (PTNYF) (PKG), Trevena Inc (TRVN), China Finance Online Co. Limited (JRJC), and Luna Innovations Incorporated (LUNA) represent 4 tech stocks on the rise on Monday. The Company is focused on improving the lives of their customers through their on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.
CHESTERBROOK, Pa., March 04, 2019 -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...
HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...
CHESTERBROOK, Pa., Feb. 05, 2019 -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Trevena, Inc. (TRVN), a biopharmaceutical company that has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. The management strongly believes in the utility of oliceridine as a new analgesic option for the management of moderate to severe acute pain for patients in hospitals or other controlled clinical settings and has laid out a detailed plan to capitalize this opportunity and gain approval for Oliceridine. Trevena was founded to translate Nobel Prize-winning research into a new generation of ground-breaking medicines.
Trevena, Inc. (TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, pursuant to which Trevena agreed to sell to the purchasers an aggregate of 10,000,000 shares of its common stock at an offering price of $1.00 per share, in a registered direct offering, for gross proceeds of $10.0 million, before deducting placement agent fees and offering expenses payable by Trevena. The offering is expected to close on or about February 1, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN) today announced the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the oliceridine New Drug Application (NDA).
Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that TRV734 data were featured in a presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology as part of Trevena’s ongoing collaboration with the National Institute on Drug Abuse (NIDA). The presentation, entitled “Modeling Opioid Maintenance Therapy in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid Receptor Agonist TRV130 on Relapse to Oxycodone Seeking,” was delivered by Yavin Shaham, Ph.D., Chief, Behavioral Neuroscience Research Branch, Intramural Research Program at NIDA.
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.